Home › NCT05062317

ctDNA-Directed Post-Hepatectomy Chemotherapy for Patients With Resectable Colorectal Liver Metastases

Risk-Stratified Adjuvant Therapy: ctDNA-Directed Post-Hepatectomy Chemotherapy for Patients With Resectable Colorectal Liver Metastases

Who can join

Ages 18 and older · All sexes

Inclusion Criteria:

* Patients ≥18 years of age with CLM undergoing elective hepatectomy with curative intent (primary colorectal primary cancer previously removed OR being removed at time of hepatectomy) after preoperative chemotherapy (i.e., FOLFOX/FOLFIRI +/- bevacizumab or panitumumab/cetuximab) from 07/01/2021 - 12/31/2023
* Must receive ≥ 4 cycles of preoperative chemotherapy

Exclusion Criteria:

* Patients with primary colorectal tumor that will remain in situ
* Inability to undergo postoperative chemotherapy, or postoperative chemotherapy not planned a priori
* Unwilling/unable to undergo blood draws for ctDNA, patient or provider-determined
* Other active malignancies requiring treatment
* Women who are pregnant

About the study

To determine if the detection of ctDNA after surgical resection of CLM can stratify patients into high and low-risk cohorts for early disease recurrence in order to inform post-operative adjuvant therapy.

What is being tested

• Leucovorin (drug)
• 5-FLUOROURACIL (drug)
• Oxaliplatin (drug)
• Irinotecan (drug)
• Capecitabine (drug)
• Bevacizumab (drug)

Sponsor: M.D. Anderson Cancer Center · Participants: 120 · Started: Apr 26, 2022

Contact the study team

• Timothy Newhook · Phone: (713) 794-1001

Official record on ClinicalTrials.gov — NCT05062317

Locations in the U.S.

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.